VRCA stock forecast
Our latest prediction for Verrica Pharmaceuticals Inc's stock price was made on the Nov. 20, 2023 when the stock price was at 3.71$.
In the short term (2weeks), VRCA's stock price should underperform the market by -2.22%. During that period the price should oscillate between -9.83% and +3.96%.
In the medium term (3months), VRCA's stock price should outperform the market by 4.47%. During that period the price should oscillate between -29.66% and +14.58%.
Get email alertsCreate a solid portfolio with VRCA
About Verrica Pharmaceuticals Inc
verrica pharmaceuticals inc., a clinical stage medical dermatology company, develops and commercializes dermatological treatments in the united states. the company's lead product candidate include vp-102 that is in phase iii clinical trial for the treatment of molluscum contagiosum; in phase ii clinical trial for the treatment of common warts; and completed phase i clinical trial for the treatment of genital warts. it is also developing cantharidin-based product candidate, vp-103 for the treatment of plantar warts. the company has a license agreement with lytix biopharma as to develop and commercialize ltx-315 for dermatologic oncology indications. verrica pharmaceuticals inc. was founded in 2013 and is headquartered in west chester, pennsylvania.
At the moment the company generates 16M USD in revenues.
On its last earning announcement, the company reported a loss of -0.93$ per share.
The book value per share is 3.95$
Three months stock forecastNov. 20, 2023
Financials
| Revenue USD | Gross Margin | Operating Income | Operating Margin | Net Income | Earnings Per Share | Dividends | Payout Ratio | Shares | Book Value Per Share | Operating Cash Flow | Cap Spending | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 16M | - | -48M | - | -30M | -0.93 | - | - | 42M | 3.95 | - | - | - |